Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNBS
Period2018-01-01 → 2018-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100FIR2.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥169m2018-01-01 → 2018-12-31StandaloneNet sales
Revenue¥229m2017-01-01 → 2017-12-31StandaloneNet sales
Revenue¥178m2016-01-01 → 2016-12-31dStandaloneNet sales (5-year summary)
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Revenue¥29m2014-01-01 → 2014-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOperating income
Operating income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOperating income
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOrdinary income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOrdinary income
Ordinary income−¥864m2016-01-01 → 2016-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥726m2014-01-01 → 2014-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2018-01-01 → 2018-12-31StandaloneIncome before income taxes
Profit before tax−¥1.1bn2017-01-01 → 2017-12-31StandaloneIncome before income taxes
Net income−¥1.2bn2018-01-01 → 2018-12-31StandaloneProfit loss
Net income−¥1.1bn2017-01-01 → 2017-12-31StandaloneProfit loss
Net income−¥931m2016-01-01 → 2016-12-31dStandaloneNet income loss (5-year summary)
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Net income−¥739m2014-01-01 → 2014-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.4bnat 2018-12-31StandaloneAssets
Total assets¥3.5bnat 2017-12-31StandaloneAssets
Total assets¥3.1bnat 2016-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.0bnat 2014-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥529mat 2018-12-31StandaloneLiabilities
Total liabilities¥594mat 2017-12-31StandaloneLiabilities
Net assets / equity¥2.9bnat 2018-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2017-12-31StandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31dStandaloneNet assets
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥4.4bnat 2014-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.5bnat 2018-12-31StandaloneCash and deposits
Cash and deposits¥2.9bnat 2017-12-31StandaloneCash and deposits
Cash & equivalents¥2.2bnat 2018-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.9bnat 2017-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.2bnat 2014-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥903m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥814m2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥342m2018-01-01 → 2018-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥132m2017-01-01 → 2017-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥257m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥6m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥233,0002014-01-01 → 2014-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-80.552014-01-01 → 2014-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥216.61at 2018-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥476.03at 2014-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio84.3%at 2018-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2014-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued13,346,000at 2018-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,200at 2014-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees30at 2018-12-31StandaloneNumber of employees
Employees29at 2017-12-31StandaloneNumber of employees
Employees30at 2016-12-31dStandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees
Employees28at 2014-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2018-01-01 → 2018-12-31¥2m
Reconciling Itemsreconcilingsegment profit2018-01-01 → 2018-12-31−¥593m
Diagnostic Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥170m
Pharmaceutical Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥485m
Total Of Reportable Segments And Otherssegment totalrevenue2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalrevenue external2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalsegment profit2018-01-01 → 2018-12-31−¥654m
Reconciling Itemsreconcilingdepreciation2017-01-01 → 2017-12-31¥1m
Reconciling Itemsreconcilingsegment profit2017-01-01 → 2017-12-31−¥537m
Diagnostic Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥104m
Pharmaceutical Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥438m
Total Of Reportable Segments And Otherssegment totalrevenue2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalrevenue external2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalsegment profit2017-01-01 → 2017-12-31−¥542m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 679
ItemContextValueUnit
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember605822000JPY
Business consignment expenses sgaPrior1YearDuration_NonConsolidatedMember147744000JPY
Business consignment expenses sgaCurrentYearDuration_NonConsolidatedMember185280000JPY
Taxes and dues sgaPrior1YearDuration_NonConsolidatedMember66314000JPY
Taxes and dues sgaCurrentYearDuration_NonConsolidatedMember63557000JPY
License fee sgaPrior1YearDuration_NonConsolidatedMember56290000JPY
License fee sgaCurrentYearDuration_NonConsolidatedMember44888000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember570541000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember605822000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember196552000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember32586000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember229139000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember229139000JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember－JPY
Net salesPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember196552000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember32586000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember229139000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesPrior1YearDuration_NonConsolidatedMember229139000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember-438213000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember-103521000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-541734000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember-536655000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember-1078389000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember－JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember1162000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember1162000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember152611000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember15938000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember168549000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember168549000JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember152611000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember15938000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember168549000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember168549000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember-484618000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2017-12-31pass rounding
balance sheet identitynon_consolidated 2018-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2016-12-31pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · net assetsnon_consolidated 2018-12-31pass
statement vs summary · operating cash flownon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · operating cash flownon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · revenuenon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · revenuenon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · total assetsnon_consolidated 2017-12-31pass
statement vs summary · total assetsnon_consolidated 2018-12-31pass